Global Pertuzumab Market Size, Share and Trends Analysis Report, By Indication (Early Breast Cancer, Metastatic Breast Cancer, and Others), and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Forecast (2022-2028)

The pertuzumab market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Pertuzumab is an antineoplastic recombinant monoclonal antibody that targets the human epidermal growth factor receptor 2 protein, often known as HER2. The medication inhibits the proliferation of human tumor cells by blocking signaling pathways that lead to cell growth arrest and apoptosis (cell death). Due to the high incidence rate and rising prevalence of bosom illness, the market is expected to grow significantly during the forecast period. These factors have prompted a slew of industry firms to try out new work methods. As a result, the present pipeline of breast cancer therapies is strong and full of potential treatments. This is expected to aid the growth of the global pertuzumab market.

The global pertuzumab market is segmented based on indication and distribution channels. Based on indication, the market is sub-segmented into early breast cancer, metastatic breast cancer, and others. Based on the distribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Among these segments, the early breast cancer segment is expected to propel the growth of the market due to the increasing prevalence of breast cancer globally. According to the World Health Organization (WHO), over 14.1 million new instances of cancer are diagnosed each year. Breast cancer is the second most common cancer form across the globe. Some of the most prevalent risk factors for breast cancer are genetic factors, obesity, lack of physical activity, alcohol use, advanced age, hormone replacement treatment following menopause, radiation exposure, early menstruation age, and having children at a late age.

The market players are also contributing significantly to the market growth by adopting various strategies, including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.  For instance, in January 2022, Bio-Rad Laboratories announced four novel anti-pertuzumab antibodies. These ready-made antibodies are designed to prevent pertuzumab and its biosimilars from binding to their target- HER2, allowing researchers to construct selective tests for bioanalysis and monitoring. In HER2-positive tumors, the HER2 protein is overexpressed, preventing cell growth and proliferation. As a therapy for certain tumors, pertuzumab and its biosimilars are designed to bind to this protein. Monovalent form antibodies are included in the novel assays, which are suitable for pharmacokinetic bridging enzyme-linked immunoassays. There are also human immunoglobulin G1 antibodies with varying affinity ranges that can be utilized as a proxy for constructive treatment.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Indication
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- F. Hoffmann-La Roche AG, Pfizer, Inc., Biocon Ltd., Amgen Inc., GlaxoSmithKline PLC, Novartis International AG, and Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Pertuzumab Market Report by Segment

By Indication

• Early Breast Cancer
• Metastatic Breast Cancer
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Pertuzumab Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa